• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

利用桑叶外泌体递送尿激酶型纤溶酶原激活剂可实现溶栓及静脉微环境重塑。

Delivering urokinase-type plasminogen activator using mulberry leaf exosomes enables thrombolysis and remodeling of venous microenvironments.

作者信息

Guan Pengpeng, Yuan Caijie, Li Jiali, Yu Kun, Xie Ruiqi, Hu Enling, Ding Weiwei, Lan Guangqian, Lu Fei

机构信息

State Key Laboratory of Laboratory of Resource Insects, College of Sericulture, Textile and Biomass Sciences, Southwest University, Chongqing 400715, China; Chongqing Engineering Research Center of Biomaterial Fiber and Modern Textile, Chongqing 400715, China.

Division of Trauma and Surgical Intensive Care Unit, Research Institute of General Surgery, Jinling Hospital, Medical School of Nanjing University, Nanjing 210002, Jiangsu Province, China.

出版信息

Int J Biol Macromol. 2024 Dec;282(Pt 2):136866. doi: 10.1016/j.ijbiomac.2024.136866. Epub 2024 Oct 23.

DOI:10.1016/j.ijbiomac.2024.136866
PMID:39454913
Abstract

In the treatment of thrombosis, conventional nanocarriers inevitably have problems, such as adverse reactions and difficulties in synthesis. Inspired by the concept of 'medicine food homology,' we extracted and purified natural exosomes from mulberry leaves as carriers for the delivery of urokinase-type plasminogen activator (uPA) for targeted therapy. The obtained mulberry leaf exosomes (MLE) possessed a desirable hydrodynamic particle size (119.4 nm), a uniform size distribution (polydispersity index = 0.174), and a negative surface charge (-23.3 mv). Before loading with uPA, MLE were grafted with cyclic RGD (cRGD) to selectively bind activated platelets for thrombus targeting. The cytometry studies revealed that MLE@cRGD has a high thrombus targeting ability about 74.3 %. Animal tests demonstrated that the delivered uPA could dissolve clots almost completely in femoral vein thrombosis models. In addition, MLE could remodel venous microenvironments by effectively eliminating reactive oxygen species (ROS) and promoting the phenotypic transformation of macrophages from M1 to M2 for venous tissue repair.

摘要

在血栓治疗中,传统纳米载体不可避免地存在不良反应和合成困难等问题。受“药食同源”概念启发,我们从桑叶中提取并纯化天然外泌体,作为尿激酶型纤溶酶原激活剂(uPA)靶向治疗的递送载体。所获得的桑叶外泌体(MLE)具有理想的流体动力学粒径(119.4 nm)、均匀的粒径分布(多分散指数 = 0.174)和负表面电荷(-23.3 mv)。在装载uPA之前,将MLE与环RGD(cRGD)接枝,以选择性结合活化血小板用于血栓靶向。细胞计数研究表明,MLE@cRGD具有约74.3%的高血栓靶向能力。动物试验表明,递送的uPA在股静脉血栓形成模型中几乎可以完全溶解血栓。此外,MLE可以通过有效消除活性氧(ROS)并促进巨噬细胞从M1型向M2型的表型转化来重塑静脉微环境,以修复静脉组织。

相似文献

1
Delivering urokinase-type plasminogen activator using mulberry leaf exosomes enables thrombolysis and remodeling of venous microenvironments.利用桑叶外泌体递送尿激酶型纤溶酶原激活剂可实现溶栓及静脉微环境重塑。
Int J Biol Macromol. 2024 Dec;282(Pt 2):136866. doi: 10.1016/j.ijbiomac.2024.136866. Epub 2024 Oct 23.
2
Monocyte urokinase-type plasminogen activator up-regulation reduces thrombus size in a model of venous thrombosis.单核细胞尿激酶型纤溶酶原激活剂上调可减小静脉血栓形成模型中的血栓大小。
J Vasc Surg. 2009 Nov;50(5):1127-34. doi: 10.1016/j.jvs.2009.06.047. Epub 2009 Aug 22.
3
Adenoviral urokinase-type plasminogen activator (uPA) gene transfer enhances venous thrombus resolution.腺病毒介导的尿激酶型纤溶酶原激活剂(uPA)基因转移可增强静脉血栓溶解。
J Vasc Surg. 2006 Nov;44(5):1085-90. doi: 10.1016/j.jvs.2006.07.020.
4
Cyclic RGD functionalized liposomes encapsulating urokinase for thrombolysis.载尿激酶环 RGD 功能化脂质体用于溶栓。
Acta Biomater. 2018 Apr 1;70:227-236. doi: 10.1016/j.actbio.2018.01.038. Epub 2018 Feb 9.
5
Drug delivery under cover of erythrocytes extends drug half-life: A thrombolytic targeting therapy utilizing microenvironment-responsive artificial polysaccharide microvesicles.红细胞掩盖下的药物递送延长了药物半衰期:一种利用微环境响应性人工多糖微囊的溶栓靶向治疗。
Carbohydr Polym. 2024 Nov 1;343:122505. doi: 10.1016/j.carbpol.2024.122505. Epub 2024 Jul 19.
6
Thrombolysis with human extrinsic (tissue-type) plasminogen activator in rabbits with experimental jugular vein thrombosis. Effect of molecular form and dose of activator, age of the thrombus, and route of administration.用人外源性(组织型)纤溶酶原激活剂对实验性颈静脉血栓形成的家兔进行溶栓治疗。激活剂分子形式和剂量、血栓形成时间以及给药途径的影响
J Clin Invest. 1983 Feb;71(2):368-76. doi: 10.1172/jci110778.
7
Comparative thrombolytic properties of tissue-type plasminogen activator (t-PA), single-chain urokinase-type plasminogen activator (u-PA) and K1K2Pu (a t-PA/u-PA chimera) in a combined arterial and venous thrombosis model in the dog.在犬动静脉联合血栓形成模型中组织型纤溶酶原激活剂(t-PA)、单链尿激酶型纤溶酶原激活剂(u-PA)和K1K2Pu(一种t-PA/u-PA嵌合体)的溶栓特性比较
J Am Coll Cardiol. 1992 May;19(6):1350-9. doi: 10.1016/0735-1097(92)90344-m.
8
Regulation of macrophage fibrinolysis during venous thrombus resolution.调控巨噬细胞纤溶在静脉血栓溶解中的作用。
Thromb Res. 2024 Nov;243:109149. doi: 10.1016/j.thromres.2024.109149. Epub 2024 Sep 14.
9
The role of urokinase plasminogen activator and plasmin activator inhibitor-1 on vein wall remodeling in experimental deep vein thrombosis.尿激酶型纤溶酶原激活物及其抑制剂-1 在实验性深静脉血栓形成中对静脉壁重构的作用。
J Vasc Surg. 2012 Oct;56(4):1089-97. doi: 10.1016/j.jvs.2012.02.054. Epub 2012 Jul 15.
10
Failure of thrombus to resolve in urokinase-type plasminogen activator gene-knockout mice: rescue by normal bone marrow-derived cells.尿激酶型纤溶酶原激活剂基因敲除小鼠中血栓溶解失败:正常骨髓来源细胞的挽救作用。
Circulation. 2003 Feb 18;107(6):869-75. doi: 10.1161/01.cir.0000050149.22928.39.

引用本文的文献

1
Plant-Derived Nanovesicles: A Promising Frontier in Tissue Repair and Antiaging.植物源纳米囊泡:组织修复与抗衰老领域的前沿希望
J Agric Food Chem. 2025 Jun 4;73(22):13159-13177. doi: 10.1021/acs.jafc.5c01547. Epub 2025 May 22.